On April 1, 2026, Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (NYSEAM:PTHS) with an “Overweight” recommendation, suggesting a potential price increase of 191.67%. The average one-year price target is projected at $59.50 per share, up from a recent closing price of $20.40. This forecast includes a low estimate of $48.48 and a high of $78.75.
Pelthos Therapeutics is expected to generate projected annual revenue of $66 million, reflecting an increase of 291.78%. Additionally, total shares owned by institutions rose by 94.35% to 899,000 shares over the last three months, with 20 funds reporting positions in the company, an increase of 11.11% quarter-over-quarter.
Notable institutional shareholders include Murchinson with 289,000 shares (8.63% ownership), Ikarian Capital with 256,000 shares (7.62% ownership), and Boothbay Fund Management with 81,000 shares (2.40% ownership), all of which significantly increased their holdings in the past quarter.
